379 related articles for article (PubMed ID: 16833167)
1. Neurohormonal and inflammatory markers as predictors of short-term outcome in patients with heart failure and cardiac resynchronization therapy.
Glick A; Michowitz Y; Keren G; George J
Isr Med Assoc J; 2006 Jun; 8(6):391-5. PubMed ID: 16833167
[TBL] [Abstract][Full Text] [Related]
2. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial.
Cleland J; Freemantle N; Ghio S; Fruhwald F; Shankar A; Marijanowski M; Verboven Y; Tavazzi L
J Am Coll Cardiol; 2008 Aug; 52(6):438-45. PubMed ID: 18672164
[TBL] [Abstract][Full Text] [Related]
3. Decrease of plasma N-terminal pro beta-type natriuretic peptide as a predictor of clinical improvement after cardiac resynchronization therapy for heart failure.
Ding LG; Hua W; Zhang S; Chu JM; Chen KP; Wang Y; Wang FZ; Chen X
Chin Med J (Engl); 2009 Mar; 122(6):617-21. PubMed ID: 19323922
[TBL] [Abstract][Full Text] [Related]
4. Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers.
George J; Patal S; Wexler D; Abashidze A; Shmilovich H; Barak T; Sheps D; Keren G
Arch Intern Med; 2005 Jun; 165(11):1304-9. PubMed ID: 15956012
[TBL] [Abstract][Full Text] [Related]
5. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath.
Maisel A; Hollander JE; Guss D; McCullough P; Nowak R; Green G; Saltzberg M; Ellison SR; Bhalla MA; Bhalla V; Clopton P; Jesse R;
J Am Coll Cardiol; 2004 Sep; 44(6):1328-33. PubMed ID: 15364340
[TBL] [Abstract][Full Text] [Related]
6. Feasibility, safety, and mid-term efficacy of cardiac resynchronization therapy in patients with severe heart failure and ventricular conduction delay: Chulalongkorn experience.
Sunsaneewitayakul B; Sitthisook S; Sangwatanaroj S; Prechawat S; Songmuang SB
J Med Assoc Thai; 2007 Jul; 90(7):1458-66. PubMed ID: 17710992
[TBL] [Abstract][Full Text] [Related]
7. Effects of cardiac resynchronization therapy on systemic inflammation and neurohormonal pathways in heart failure.
Tarquini R; Guerra CT; Porciani MC; Michelucci A; Padeletti M; Ricciardi G; Chiostri M; Jelic S; Padeletti L
Cardiol J; 2009; 16(6):545-52. PubMed ID: 19950091
[TBL] [Abstract][Full Text] [Related]
8. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function.
Valle R; Aspromonte N; Feola M; Milli M; Canali C; Giovinazzo P; Carbonieri E; Ceci V; Cerisano S; Barro S; Milani L
J Card Fail; 2005 Sep; 11(7):498-503. PubMed ID: 16198244
[TBL] [Abstract][Full Text] [Related]
9. Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure.
Ghali JK; Boehmer J; Feldman AM; Saxon LA; Demarco T; Carson P; Yong P; Galle EG; Leigh J; Ecklund FL; Bristow MR
J Card Fail; 2007 Nov; 13(9):769-73. PubMed ID: 17996827
[TBL] [Abstract][Full Text] [Related]
10. Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: time courses and prediction of response.
Boriani G; Regoli F; Saporito D; Martignani C; Toselli T; Biffi M; Francolini G; Diemberger I; Bacchi L; Rapezzi C; Ferrari R; Branzi A
Peptides; 2006 Jul; 27(7):1776-86. PubMed ID: 16621149
[TBL] [Abstract][Full Text] [Related]
11. Baseline and 6-month B-type natriuretic peptide changes are independent predictors of events in patients with advanced heart failure awaiting cardiac transplantation.
Campana C; Pasotti M; Klersy C; Alessandrino G; Albertini R; Magrini G; Ghio S; Tavazzi L
J Cardiovasc Med (Hagerstown); 2009 Sep; 10(9):671-6. PubMed ID: 19444135
[TBL] [Abstract][Full Text] [Related]
12. Lower rather than higher levels of B-type natriuretic peptides (NT-pro-BNP and BNP) predict short-term mortality in end-stage heart failure patients treated with nesiritide.
Miller WL; Burnett JC; Hartman KA; Henle MP; Burritt MF; Jaffe AS
Am J Cardiol; 2005 Sep; 96(6):837-41. PubMed ID: 16169373
[TBL] [Abstract][Full Text] [Related]
13. [Usefulness of brain natriuretic peptide to evaluate patients with heart failure treated with cardiac resynchronization].
Hernández Madrid A; Miguelañez Díaz M; Escobar Cervantes C; Blanco Tirados B; Marín I; Bernal E; Zamora J; Cordova González FJ; Alfonso Pérez M; Limón L; González Rebollo JM; Moya Mur JL; Moro C
Rev Esp Cardiol; 2004 Apr; 57(4):299-305. PubMed ID: 15104983
[TBL] [Abstract][Full Text] [Related]
14. B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure.
de Groote P; Dagorn J; Soudan B; Lamblin N; McFadden E; Bauters C
J Am Coll Cardiol; 2004 May; 43(9):1584-9. PubMed ID: 15120815
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of QRS duration to predict response to cardiac resynchronization therapy in patients with end-stage heart failure.
Mollema SA; Bleeker GB; van der Wall EE; Schalij MJ; Bax JJ
Am J Cardiol; 2007 Dec; 100(11):1665-70. PubMed ID: 18036366
[TBL] [Abstract][Full Text] [Related]
16. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes.
Chong AY; Freestone B; Patel J; Lim HS; Hughes E; Blann AD; Lip GY
Am J Cardiol; 2006 Mar; 97(5):671-5. PubMed ID: 16490435
[TBL] [Abstract][Full Text] [Related]
17. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure.
Fonarow GC; Peacock WF; Phillips CO; Givertz MM; Lopatin M;
J Am Coll Cardiol; 2007 May; 49(19):1943-50. PubMed ID: 17498579
[TBL] [Abstract][Full Text] [Related]
18. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony.
Fruhwald FM; Fahrleitner-Pammer A; Berger R; Leyva F; Freemantle N; Erdmann E; Gras D; Kappenberger L; Tavazzi L; Daubert JC; Cleland JG
Eur Heart J; 2007 Jul; 28(13):1592-7. PubMed ID: 17298973
[TBL] [Abstract][Full Text] [Related]
19. Plasma brain natriuretic peptide predicts short-term clinical outcome in heart failure patients with restrictive filling pattern.
Feola M; Aspromonte N; Milani L; Bobbio M; Bardellotto S; Barro S; Giovinazzo P; Noventa F; Valle R
J Card Fail; 2008 Jun; 14(5):420-5. PubMed ID: 18514935
[TBL] [Abstract][Full Text] [Related]
20. Multimarker strategy for the prediction of 31 days cardiac death in patients with acutely decompensated chronic heart failure.
Zairis MN; Tsiaousis GZ; Georgilas AT; Makrygiannis SS; Adamopoulou EN; Handanis SM; Batika PC; Prekates AA; Velissaris D; Kouris NT; Mytas DZ; Babalis DK; Karidis KS; Foussas SG
Int J Cardiol; 2010 Jun; 141(3):284-90. PubMed ID: 19157603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
